Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers

We developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA-sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance in HER2-mutant breast cancer PDXs was also associated with TORC1 hyperactivity. Gen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Cell
Asıl Yazarlar: Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, Ericsson, Paula González, Servetto, Alberto, Rosario, Mariela H., Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Brewer, Monica R., Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7301608/
https://ncbi.nlm.nih.gov/pubmed/31978326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.12.013
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller